deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04339413

A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)

An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease

Sponsor: Hoffmann-La Roche

Interventions Gantenerumab
Updated 24 times since 2020 Last updated: Dec 21, 2023 Started: May 22, 2020 Primary completion: Jan 4, 2023 Completion: Jan 4, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).

This PHASE3 trial investigates Alzheimer Disease and is currently terminated or withdrawn. Hoffmann-La Roche leads this study, which shows 24 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

24 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Feb 2023 — Feb 2024 [monthly]

    Terminated PHASE3

    Status: Active Not RecruitingTerminated

Show 19 earlier versions
  1. Jan 2023 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  8. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  9. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  10. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  11. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  12. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  13. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  14. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  15. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  16. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  17. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  18. Jun 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE3

  19. May 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .